Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Tyrosine kinase inhibitory activity of dehydroabietylamine derivatives tested by homogeneous time-resolved fluorescence based high throughput screening model.

Zhou TT, He L, Yan M, Zhang LY, He JG, Rao XP.

Chin J Nat Med. 2013 Sep;11(5):506-13. doi: 10.1016/S1875-5364(13)60092-8.

PMID:
24359775
2.

[Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors].

Li XG, Wang GF, Zhang JY, Wu SY, Xu W, Wu SG, Zhang JJ.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Aug;29(8):1612-4. Chinese.

3.

Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.

Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.

Eur J Med Chem. 2013 Sep;67:373-83. doi: 10.1016/j.ejmech.2013.06.057. Epub 2013 Jul 6.

PMID:
23900004
5.

Structure-activity relationship of halophenols as a new class of protein tyrosine kinase inhibitors.

Feng XE, Zhao WY, Ban SR, Zhao CX, Li QS, Lin WH.

Int J Mol Sci. 2011;12(9):6104-15. doi: 10.3390/ijms12096104. Epub 2011 Sep 19.

6.

HTRF Kinase Assay Development and Methods in Inhibitor Characterization.

Jia Y, Manuia M, Juarez J.

Methods Mol Biol. 2016;1360:1-18. doi: 10.1007/978-1-4939-3073-9_1.

PMID:
26501898
8.

Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening.

Lin LG, Xie H, Li HL, Tong LJ, Tang CP, Ke CQ, Liu QF, Lin LP, Geng MY, Jiang H, Zhao WM, Ding J, Ye Y.

J Med Chem. 2008 Aug 14;51(15):4419-29. doi: 10.1021/jm701501x. Epub 2008 Jul 9.

PMID:
18610999
9.
10.

A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKbeta-NEMO interaction.

Gotoh Y, Nagata H, Kase H, Shimonishi M, Ido M.

Anal Biochem. 2010 Oct 1;405(1):19-27. doi: 10.1016/j.ab.2010.05.028. Epub 2010 Jun 1.

PMID:
20522330
11.

Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.

Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Warnke LA.

Bioorg Med Chem. 2008 May 15;16(10):5514-28. doi: 10.1016/j.bmc.2008.04.019. Epub 2008 Apr 14.

12.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.

J Med Chem. 1997 Feb 14;40(4):413-26.

PMID:
9046331
13.

Synthesis and in vitro protein tyrosine kinase inhibitory activity of furan-2-yl(phenyl)methanone derivatives.

Zheng FL, Ban SR, Feng XE, Zhao CX, Lin W, Li QS.

Molecules. 2011 Jun 14;16(6):4897-911. doi: 10.3390/molecules16064897.

14.

Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.

Smith L 2nd, Piatnitski EL, Kiselyov AS, Ouyang X, Chen X, Burdzovic-Wizemann S, Xu Y, Pan W, Chen X, Wang Y, Rosler RL, Patel SN, Chiang HH, Milligan DL, Columbus J, Wong WC, Doody JF, Hadari YR.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1643-6. Epub 2006 Jan 18. Erratum in: Bioorg Med Chem Lett. 2006 Jul 15;16(14):3869. Pan, Weitao [added]; Chen, Xin [added].

PMID:
16412636
15.

Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.

Lü S, Zheng W, Ji L, Luo Q, Hao X, Li X, Wang F.

Eur J Med Chem. 2013 Mar;61:84-94. doi: 10.1016/j.ejmech.2012.07.036. Epub 2012 Jul 27.

PMID:
22867529
17.

An improved zinc cocktail-mediated fluorescence polarization-based kinase assay for high-throughput screening of kinase inhibitors.

Chopra P, Nanda K, Chatterjee M, Bajpai M, Dastidar SG, Ray A.

Anal Biochem. 2008 Sep 1;380(1):143-5. doi: 10.1016/j.ab.2008.05.042. Epub 2008 Jun 3.

PMID:
18570885
18.

Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.

Usui T, Ban HS, Kawada J, Hirokawa T, Nakamura H.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):285-8. Epub 2007 Oct 30.

PMID:
17983745
19.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.

J Pharm Belg. 1997 Mar-Apr;52(2):88-96. Review.

PMID:
9193132
20.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099

Supplemental Content

Support Center